AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03395938 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current practice
Description: This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
Study NCT01708187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clarix™1k graft
Description: Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
Study NCT00810160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ProlactPlus
Description: Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
Study NCT00810160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GOS galacto-oligosaccharides
Description: Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
Study NCT00810160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
Study NCT00810160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis
Description: Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
Study NCT00942708 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoxetine
Description: Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID
Study NCT02243566 — intervention group
Intervention type: DRUG
Intervention: MicardisPlus®
Study NCT01134484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: * INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~* REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)
Study NCT01134484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: * INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70
Study NCT01134484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: * INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70
Study NCT02722187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic varicocelectomy
Study NCT01134484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: * INDUCTION THERAPY~  1. VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~ 2. TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~* AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~  1. VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~ 2. TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)
Study NCT01134484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * INDUCTION THERAPY~  1. VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~ 2. TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~* AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~  1. VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~ 2. TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)
Study NCT01134484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell (PBSC) collection
Description: * Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~* G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection
Study NCT01134484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell (PBSC) collection
Description: * Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~* G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection
Study NCT01134484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First Autologous Transplantation
Description: * HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days
Study NCT01134484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First Autologous Transplantation
Description: * HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days
Study NCT01134484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second Autologous Transplantation
Description: * HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days
Study NCT01134484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Autologous Transplantation
Description: * HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days
Study NCT00477451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled Staccato Alprazolam Placebo
Study NCT00477451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled alprazolam 1 mg
Description: Inhaled Staccato Alprazolam 1 mg
Study NCT00477451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato Alprazolam 2 mg
Study NCT00477451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV doxapram
Description: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
Study NCT00477451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV doxapram
Description: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
Study NCT02551848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study NCT01964365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto 20mg
Description: tablet, rosuvastatin 20mg
Study NCT01964365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135mg
Description: capsule, fenofibric acid 135mg
Study NCT01964365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto 20mg, Fenofibric acid 135mg
Description: rosuvastatin 20mg, Fenofibric acid 135mg
Study NCT04155385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement
Description: The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
Study NCT04155385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement
Description: The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
Study NCT04155385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
Study NCT02730247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
Study NCT02730247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
Study NCT00743080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX
Description: Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation.
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol.
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of >1000/μL
Study NCT04224558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis catheter placement
Description: Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
Study NCT04224558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\^6 CD34+ cells/kg body weight.
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin (rabbit)
Description: Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lymphocyte immune globulin
Description: Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
Study NCT04224558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Infusion
Description: PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
Study NCT04224558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
Study NCT01809366 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: seminal plasma insemination
Study NCT01809366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: seminal plasma insemination
Study NCT00743080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1
Description: Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation.
Study NCT02036788 — intervention group
Intervention type: OTHER
Intervention: Occlusion test
Description: Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
Study NCT02036788 — intervention group
Intervention type: OTHER
Intervention: Thoraco-abdominal compressions
Description: Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
Study NCT00625560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 1.0 mg QD
Study NCT01292473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied lyophilized in vials.
Study NCT01292473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied lyophilized in vials.
Study NCT05342688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-specific practice of upper extremity functions
Description: The intervention will consist of training of items from the Wolf motor function test.
Study NCT05342688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-specific practice of upper extremity functions
Description: The intervention will consist of training of items from the Wolf motor function test.
Study NCT04354688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3 Certain Tapered Implant
Description: Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
Study NCT00625560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study NCT03552003 — intervention group
Intervention type: OTHER
Intervention: Treatment for clinical practise
Description: Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
Study NCT00847535 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous muscle cell injection
Description: Injection of autologous muscle cells
Study NCT04354688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T3 Certain Tapered Implant
Description: Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
Study NCT05033535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubatril Allisartan medoxomil
Description: Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension
Study NCT05033535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan Medoxomil
Description: Efficacy for lowering blood pressure of Olmesartan medoxomil
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05186462
Description: single oral administration of 100 microgram
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05089771
Description: single intravenous infusion of 100 microgram of PF-05089771
Study NCT01463579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home.
Study NCT01463579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
Study NCT01188863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX4211 (150 mg tablets)
Description: Single oral dose of two 150 mg tablets LX4211
Study NCT01188863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX4211 (50 mg tablets)
Description: Single oral dose of six 50 mg tablets LX4211
Study NCT01188863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX4211 (liquid)
Description: Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05089771
Description: single oral administration of 100 microgram PF-05089771
Study NCT01665105 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
Study NCT01665105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.